Juniper Pharmaceuticals, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Juniper Pharmaceuticals, Inc. on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juniper Pharmaceuticals, Inc. (NASDAQGS: JNP) violated federal securities laws by issuing materially misleading information to the investing public. Juniper Pharmaceuticals focuses on developing therapeutics that address unmet medical needs in women’s health.

Juniper Pharmaceuticals Announces Restatement of Financials

On October 24, 2016, Juniper Pharmaceuticals announced in its Form 8-K filed with the U.S. Securities and Exchange Commission that it would have to restate its financial statements since 2013. The company stated that the errors concerned revenue recognition related to a supply agreement with an affiliate of Germany’s Merck KGaA. On this news, Juniper Pharmaceuticals stock fell 10% in early morning trading on October 25, 2016.

Juniper Pharmaceuticals Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.


Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information

    Send This Post